Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation

Current Cardiology Reviews

Volumn 10, Issue 4, 2014, Pages 297-302

  Halperin, Jonathan L ^a   Dorian, Paul ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Anticoagulation; Antithrombotic therapy; Atrial fibrillation; Factor IIa inhibitors; Factor Xa inhibitors; Stroke; Thrombin; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; THROMBIN INHIBITOR;

AGE; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; KIDNEY FAILURE; MONITORING; NON VALVULAR ATRIAL FIBRILLATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SECONDARY PREVENTION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; FACTOR XA; HUMANS; PROTHROMBIN; STROKE; THROMBIN; WARFARIN;

EID: 84904747014     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/1573403X10666140513104523     Document Type: Article

References (35)

1. Independent predictors of stroke in patients with atrial fibrillation. Neurology 2007; 69: 546-4.
2. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003; 290: 1049-56.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
4. Diener HC. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation: Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006; 21: 279-93.
5. Connolly S, Ezekowitz M. Correspondence: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 2671-5.
6. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2010; 363: 1875-6.
7. Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 2012; 52 (suppl): 119S-25S.
8. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.
9. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
10. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
11. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160: 635-41.
12. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial/Clinical Perspective. Circulation. 2012; 125: 669-76.
13. Food and Drug Administration. FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin [press release]. May 13, 2014 (http://www. fda. gov/Drugs/DrugSafety/ucm396470. htm).
14. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
15. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9-19.
16. APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation 2009; 119: 2877-85.
17. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE-LY trial. Stroke 2012; 43: 1511-7.
18. Stroke in Atrial Fibrillation Working Group. Independent predictors of stroke in atrial fibrillation: A systematic review. Neurology 2007; 69: 546-54.
19. Palareti G, Cosmi B. Bleeding with anticoagulation therapy: Who is at risk, and how best to identify such patients. Thromb Haemost 2009; 102: 268-78.
20. Diener H-C, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fi brillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157-63.
21. Hankey G, Patel M, Stevens S, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315-22.
22. Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503-11.
23. Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363-9.
24. Oleson JB, Lip GHY, Kamper A-L, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367: 625-35.
25. Piccini JP, Stevens SR, Chang YC, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Derivation and validation of the R2CHADS2index in the ROCKET AF and ATRIA study cohorts. Circulation 2013; 127(2): 224-32.
26. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the Randomized Evaluation of Long-term Anticoagulant Therapy (RELY) trial. Circulation 2011; 123: 2363-72.
27. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48: 1-22.
28. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32(19): 2387-94.
29. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821-30.
30. Ntaios G, Papavasileiou V, Diener HC, et al. Nonvitamin-kantagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: A systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43: 3298-304.
31. Halperin JL, Wojdyla D, Piccini JP, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET-AF trial. Stroke 2012; 43 Suppl, A-148.
32. Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; Feb 20. [Epub ahead of print].
33. Wallentin L, Yusuf S, Ezekowitz MD, et al. Effi cacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 2010; 376: 975-83.
34. Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc 2014; (Published online April 22, 2014; 3: e000521. doi: 10. 1161/JAHA. 113. 000521.).
35. Spyropoulos AC, Goldenberg NA, Kessler CM, et al. Comparative effectiveness and safety of the novel oral anticoagulants: Do the pivotal clinical trials point to a new paradigm? J Thromb Haemost 2012; 10: 2621-4.